These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 28214007)
1. [Impact of Her2 and BRCA1/2 status in high-dose chemotherapy and autologous stem cells transplantation in the treatment of breast cancer: The Institut Paoli Calmettes' experience]. Boudin L; Chabannon C; Sfumato P; Sabatier R; Bertucci F; Tarpin C; Provansal M; Houvenaeghel G; Lambaudie E; Tallet A; Resbeut M; Charafe-Jauffret E; Calmels B; Lemarie C; Boher JM; Extra JM; Viens P; Gonçalves A Bull Cancer; 2017 Apr; 104(4):332-343. PubMed ID: 28214007 [TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation. Boudin L; Chabannon C; Sfumato P; Sabatier R; Bertucci F; Tarpin C; Provansal M; Houvenaeghel G; Lambaudie E; Tallet A; Resbeut M; Charafe-Jauffret E; Calmels B; Lemarie C; Boher JM; Extra JM; Viens P; Gonçalves A Eur J Cancer; 2016 Apr; 57():118-26. PubMed ID: 26918737 [TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study. Boudin L; Gonçalves A; Sfumato P; Sabatier R; Bertucci F; Tarpin C; Provansal M; Houvenaeghel G; Lambaudie E; Tallet A; Resbeut M; Charafe-Jauffret E; Calmels B; Lemarie C; Boher JM; Extra JM; Viens P; Chabannon C J Cancer; 2016; 7(14):2077-2084. PubMed ID: 27877223 [No Abstract] [Full Text] [Related]
4. Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Boudin L; Gonçalves A; Sabatier R; Moretta J; Sfumato P; Asseeva P; Livon D; Bertucci F; Extra JM; Tarpin C; Houvenaeghel G; Lambaudie E; Tallet A; Resbeut M; Sobol H; Charafe-Jauffret E; Calmels B; Lemarie C; Boher JM; Viens P; Eisinger F; Chabannon C Bone Marrow Transplant; 2016 Aug; 51(8):1082-6. PubMed ID: 27042835 [TBL] [Abstract][Full Text] [Related]
5. [Combination of high-dose chemotherapy with autologous hematopoietic stem cell transplantation for recurrent and high-risk breast cancer: a pilot study]. Shi Y; Pan F; Han X Zhonghua Yi Xue Za Zhi; 1999 Dec; 79(12):890-3. PubMed ID: 11715500 [TBL] [Abstract][Full Text] [Related]
6. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer. Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752 [TBL] [Abstract][Full Text] [Related]
7. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors. Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742 [TBL] [Abstract][Full Text] [Related]
8. High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: a 10-year experience. Laport GF; Grad G; Grinblatt DL; Bitran JD; Williams SF Bone Marrow Transplant; 1998 Jan; 21(2):127-32. PubMed ID: 9489628 [TBL] [Abstract][Full Text] [Related]
9. Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancer. VanderWalde A; Ye W; Frankel P; Asuncion D; Leong L; Luu T; Morgan R; Twardowski P; Koczywas M; Pezner R; Paz IB; Margolin K; Wong J; Doroshow JH; Forman S; Shibata S; Somlo G Biol Blood Marrow Transplant; 2012 Aug; 18(8):1273-80. PubMed ID: 22306735 [TBL] [Abstract][Full Text] [Related]
10. Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: results from the Italian national registry. Pedrazzoli P; Martinelli G; Gianni AM; Da Prada GA; Ballestrero A; Rosti G; Frassineti GL; Aieta M; Secondino S; Cinieri S; Fedele R; Bengala C; Bregni M; Grasso D; De Giorgi U; Lanza F; Castagna L; Bruno B; Martino M; Biol Blood Marrow Transplant; 2014 Apr; 20(4):501-6. PubMed ID: 24374214 [TBL] [Abstract][Full Text] [Related]
11. A phase II study of two cycles of high-dose chemotherapy with autologous stem cell support in patients with metastatic breast cancer who meet eligibility criteria for a single cycle. Bashey A; Corringham S; Garrett J; Lane TA; Gilpin EA; Corringham RE; Law P; Ho AD Bone Marrow Transplant; 2000 Mar; 25(5):519-24. PubMed ID: 10713629 [TBL] [Abstract][Full Text] [Related]
12. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care. Holland HK; Dix SP; Geller RB; Devine SM; Heffner LT; Connaghan DG; Hillyer CD; Hughes LL; Miller RL; Moore MR; Winton EF; Wingard JR J Clin Oncol; 1996 Apr; 14(4):1156-64. PubMed ID: 8648370 [TBL] [Abstract][Full Text] [Related]
13. Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study. Jin X; Jiang YZ; Chen S; Yu KD; Shao ZM; Di GH Oncotarget; 2015 Apr; 6(11):9600-11. PubMed ID: 25826079 [TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG. Kuroi K; Toi M; Ohno S; Nakamura S; Iwata H; Masuda N; Sato N; Tsuda H; Kurosumi M; Akiyama F Breast Cancer; 2015 Sep; 22(5):486-95. PubMed ID: 24338638 [TBL] [Abstract][Full Text] [Related]
15. Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer. Kröger N; Frick M; Gluz O; Mohrmann S; Metzner B; Jackisch C; Ko Y; Lindemann HW; Meier CR; Lohrmann HP; Ruffert U; Hänel M; Bodenstein H; Neubauer A; Ehninger G; Wolf HH; Kolbe K; Burock K; Zander AR; Nitz U J Clin Oncol; 2006 Aug; 24(24):3919-26. PubMed ID: 16921043 [TBL] [Abstract][Full Text] [Related]
16. Feasibility and low toxicity of early radiotherapy after high-dose chemotherapy and autologous stem cell transplantation for patients with high-risk stage II-III and locally advanced breast carcinoma. Stemmer SM; Pfeffer MR; Rizel S; Hardan I; Goffman J; Gezin A; Neumann A; Kitsios P; Alezra D; Brenner HJ Cancer; 2001 Jun; 91(11):1983-91. PubMed ID: 11391576 [TBL] [Abstract][Full Text] [Related]
17. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. Crump M; Gluck S; Tu D; Stewart D; Levine M; Kirkbride P; Dancey J; O'Reilly S; Shore T; Couban S; Girouard C; Marlin S; Shepherd L; Pritchard KI J Clin Oncol; 2008 Jan; 26(1):37-43. PubMed ID: 18025439 [TBL] [Abstract][Full Text] [Related]
18. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091 [TBL] [Abstract][Full Text] [Related]
19. Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma. Arun B; Slack R; Gehan E; Spitzer T; Meehan KR Cancer; 1999 Jan; 85(1):93-9. PubMed ID: 9921979 [TBL] [Abstract][Full Text] [Related]
20. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease. de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]